LSD Shows Promise in Alleviating Anxiety, Experts Caution on Use

A recent study indicates that lysergic acid diethylamide, commonly referred to as LSD, could play a significant role in alleviating anxiety. This marks a notable development in the exploration of psychedelic substances for mental health treatment.

For the first time, researchers have evaluated the safety and efficacy of a pharmaceutical formulation of LSD, known as MM120, specifically as a standalone treatment for individuals suffering from moderate to severe generalized anxiety disorder. The study, led by Dr. Daniel Karlin, chief medical officer at MindMed, a biopharmaceutical company based in New York, unfolds new possibilities at the intersection of psychedelics and mental health.

The findings were published in the Journal of the American Medical Association, contributing to the growing body of research examining pharmaceuticals developed from psychedelic compounds.

Study Overview and Methodology

In this study, nearly 200 adults aged between 18 and 74 participated. Participants received either a single oral dose of LSD at different strengths or a placebo over a three-month period. The trials took place in private rooms, each monitored by two trained personnel who ensured participant safety for a minimum of 12 hours. Importantly, no psychotherapy accompanied the dosing sessions.

Researchers diligently tracked changes in the participants’ anxiety levels by measuring anxiety scores at weeks 1, 2, 4, 8, and 12, with a particular focus on week 4 as a critical evaluation point. The results were promising; those who received the highest dosage experienced significantly reduced anxiety scores compared to others.

Remarkable Results with High Doses

By the end of the 12-week study, 65% of patients administered 100 milligrams of LSD reported benefits, with nearly half of them achieving complete remission from anxiety symptoms. Researchers also observed significant improvements among participants regarding depressive symptoms when treated with higher LSD dosages.

Dr. Karlin noted that the effects were often immediate, though the psychedelic experience was accompanied by several side effects including nausea, headaches, and hallucinations. Optimal results were associated with the 100-milligram dose, whereas lower doses (25 milligrams and 50 milligrams) did not yield significant benefits.

Psychedelic Drug Regulation and Future Trials

Understanding the complexities and risks associated with psychedelic substances is crucial. LSD is classified as a Schedule I drug, suggesting a high potential for abuse and no currently accepted medical use, as outlined by the Drug Enforcement Administration. Under this classification, prescribing and using LSD in medical treatment remains illegal unless specific research protocols are followed.

Looking forward, MindMed plans to conduct two large-scale late-stage trials to examine the effects of LSD over an extended period. If successful, the company intends to submit its findings to the U.S. Food and Drug Administration in hopes of achieving approval.

Expert Opinions on the Findings

Dr. Marc Siegel, a senior medical analyst, expressed caution regarding the enthusiasm surrounding the study’s findings. While he acknowledged the promising results observed in the trial, he also emphasized the necessity of meticulous research, particularly concerning both the potential side effects and the drug’s effectiveness.

Additional side effects documented in past studies include mood swings, paranoia, increased heart rate, and long-lasting psychosis, reminding us of the profound psychological impacts that substances like LSD can invoke.

Hadas Alterman, an attorney with a focus on psychedelic medicine, highlighted the regulatory and cultural shift toward reconsidering psychedelics. The interest in research on LSD and similar substances has rebounded, partly due to historical context when the 1962 Kefauver–Harris Amendments significantly restricted their study and use.

The Road Ahead for Psychedelic Research

Alterman noted that the regulatory environment now encourages a thoughtful re-examination of psychedelics. With figures such as Health and Human Services Secretary Robert F. Kennedy Jr. and Department of Veterans Affairs Secretary Doug Collins showing interest in investigating psychedelic therapy, the prospects for legitimate research and application may be stronger than in previous decades.